L&T-TECHNOLOGY
15.9.2023 10:31:32 CEST | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global digital engineering and R&D company, today announced the launch of the second-annual Digital Engineering Awards, in association with Information Services Group (ISG), a leading global technology research and advisory firm, and business news channel CNBC TV-18 in India.
The Digital Engineering Awards recognize and celebrate business and technology trailblazers who are crafting a smarter and more sustainable world through transformative ideas that leverage digital engineering.
Enterprises and their service providers are invited to submit nominations through October 5, with winners announced during a gala awards celebration on December 6 in Dallas, Tex., U.S.A. Enterprise award winners, selected by a global panel of industry experts, including representatives of ISG, will be named in nine categories – five team awards and four individual awards:
Engineering the Change Team Awards
- Digital Transformation of the Year
- Top Sustainability Initiative
- Digital Engineering Program of the Year
- Engineering Product of the Year
- Value Realization
Engineering at Heart Individual Awards
- Distinguished Digital Engineer
- Digital Engineer of the Year
- Woman Engineer of the Year
- Innovator of the Year
The inaugural Digital Engineering Awards gala was held last year in Jersey City, N.J., United States, with 120 nominees, including over 70 industry-leading global enterprises, in attendance. Winners, both individual engineers and teams, included representatives from Airbus, American Honda Motor Co., Inc./ Honda Marine, Chevron, ExxonMobil, GE Healthcare, Intel Corporation, Microsoft, Rolls-Royce, and Qualcomm Technologies.
Remarking on the occasion, Mr. Amit Chadha, CEO and Managing Director at L&T Technology Services said, "We take immense pride in having witnessed the tremendous success of the maiden Digital Engineering Awards, which celebrated disruptive innovations across a broad spectrum of deep technologies, spanning automotive, aerospace, industrial products, telecom, plant engineering, and medical devices. As we persist in our unwavering commitment to engineering research and development, aiming to shape a future enabled by engineering marvels, we are eager to extend our endeavors in spotlighting extraordinary innovation and leadership that spearheads transformation towards a sustainable, digitally empowered tomorrow."
“Digital engineering is the fabric that connects all facets of the digital world and makes future innovations possible,” said Michael P. Connors, Chairman and CEO of ISG. “Following the great success of the inaugural Digital Engineering Awards, we are delighted once again to collaborate with L&T Technology Services and CNBC-TV18 to recognize the outstanding work of individuals and teams whose groundbreaking innovations will shape the digital landscape for years to come.”
“The Digital Engineering Awards have a key role to play in celebrating the new-age digital solutions that are driving immense growth in the ER&D sector. Our role as media partner with L&T Technology Services aligns perfectly with the long-standing objective of our brands – CNBC-TV18 and Moneycontrol – to educate audiences about innovations and developments in the worlds of technology and business,” said S. Shivakumar: President, News18 Studios.
About the Digital Engineering Awards
The Digital Engineering Awards bring together industry leaders to recognize outstanding achievements in the R&D domain, and to help global organizations give shape to their transformative ideas. The Awards are produced by L&T Technology Services in association with ISG, with CNBC TV18 as a media partner. For more about the Awards, visit this website (www.digitalengineeringawards.com) or contact us at info@digitalengineeringawards.com
About Network18
Network18 Media & Investments Limited is a major Indian media conglomerate owned by Reliance Industries. The company operates a wide array of channels spanning news, entertainment, and digital content. Its portfolio includes CNBC-TV18, CNBC-AWAAZ, CNBC-Bajar, CNN-NEWS18, News18 India, and News18 regional news channels across languages and markets.
About ISG
ISG (Information Services Group) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,300 employees spread across 22 global design centers, 28 global sales offices and 102 innovation labs as of June 30, 2023. For more information, please visit https://www.LTTS.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914274834/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom